Search research articles
Contact Us
Filters
Showing results (101-110 of 153) with videos related to
Page
of 16
Sort By:
Cancers
|
July 5, 2019
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment
Nicole Wong Doo, Victoria M White, Kara Martin, et al.
Internal Medicine Journal
|
February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Hang Quach, Simon Benson, Helen Haysom, et al.
American Journal of Hematology
|
February 6, 2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
Simon J Harrison, Hang Quach, Emma Link, et al.
Expert Review of Hematology
|
August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy
Valeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Molecular Therapy. Oncology
|
April 10, 2024
Targeting the ribosome to treat multiple myeloma
Kylee H Maclachlan, Kezia Gitareja, Jian Kang, et al.
BMJ Neurology Open
|
September 19, 2024
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study
Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
Leukemia
|
May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
Annals of Hematology
|
March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
Chan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
BMJ Neurology Open
|
March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapy
Daniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 153) with videos related to
Sort By:
Page
of 16
Cancers
|
July 5, 2019
The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment
Nicole Wong Doo, Victoria M White, Kara Martin, et al.
Internal Medicine Journal
|
February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Hang Quach, Simon Benson, Helen Haysom, et al.
American Journal of Hematology
|
February 6, 2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
Simon J Harrison, Hang Quach, Emma Link, et al.
Expert Review of Hematology
|
August 1, 2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy
Valeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, et al.
Molecular Therapy. Oncology
|
April 10, 2024
Targeting the ribosome to treat multiple myeloma
Kylee H Maclachlan, Kezia Gitareja, Jian Kang, et al.
BMJ Neurology Open
|
September 19, 2024
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study
Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
Leukemia
|
May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
Annals of Hematology
|
March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
Chan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
BMJ Neurology Open
|
March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapy
Daniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Page
of 16